Indonesia Halal Certification for Class A Medical Devices: The October 18, 2026 Deadline
Medical Device Global Market AccessShow Notes
Indonesia is implementing mandatory Halal certification for Class A medical devices, with a critical deadline of October 18, 2026. This episode breaks down what the Halal Product Assurance Law means for manufacturers of low-risk devices. We cover the scope of affected products, the intricacies of the certification process overseen by the BPJPH, and the comprehensive requirements that extend from raw materials to final distribution. We provide practical, actionable steps for regulatory, quality, and market-access teams to prepare for this significant compliance shift and maintain access to the Indonesian market.
Key Questions: - What is Indonesia's Halal Product Assurance Law and how does it apply to medical devices? - Which Class A medical devices are affected by the October 18, 2026 deadline? - What does the Halal certification process involve for medical device manufacturers? - How are raw materials, production processes, and supply chains evaluated for Halal compliance? - What practical steps should manufacturers take now to prepare for this new requirement? - What is the role of Indonesia's Halal Product Assurance Organizing Agency (BPJPH)? - How can companies begin auditing their supply chain for Halal-compliant materials? - What are the strategic considerations for deciding whether to pursue certification? - What are the consequences of non-compliance after the deadline? - Where can manufacturers find accredited Halal Inspection Agencies (LPH)?
Sources: - https://www.medenvoy.com/resources/medical-device-regulatory-calendar - https://www.bplawyers.co.id/en/halal-certification-for-medical-devices-in-indonesia/
How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access global markets. We help you navigate complex requirements like Indonesia's Halal certification by developing clear regulatory strategies, managing technical dossier submissions, and acting as your local representative. Our combination of in-country experts and advanced AI tools streamlines the registration process, saving you time and resources. Whether you are assessing your product portfolio, auditing your supply chain, or managing submissions, our team is equipped to ensure you meet deadlines and maintain market presence. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI tools and global device database at https://pureglobal.ai.
More from Medical Device Global Market Access
Swissmedic has activated the importer linking function in the swissdamed database as of October 1, 2026. This creates a new mandatory step for Swiss importers, who now have until April 1, 2027, to electronically link their actor registration (CHRN) to the devices they place on the market. This episode breaks down the new obligation, explains its dependency on prior device registration by manufacturers and Swiss Authorized Representatives (CH-REPs), and outlines practical steps for all economic operators to ensure compliance before the deadline.
On October 6, 2026, the European Commission selected the first group of high-risk medical devices to undergo a Joint Clinical Assessment (JCA) under the new EU Health Technology Assessment Regulation (HTAR). This episode explains what this pivotal moment means for medical device manufacturers, which device categories are impacted, and how the JCA will reshape the pathway for pricing, reimbursement, and market access across the European Union. We discuss the heightened evidence requirements and provide practical steps for regulatory and market access teams to prepare for this new centralized assessment system.
Australia's Therapeutic Goods Administration (TGA) has updated its guidance on fee reductions for medical device conformity and ARTG application audits. Effective October 1, 2026, these changes introduce a new fee model for design examinations based on Unique Product Identifier (UPI) components, increase certain recertification fees, and raise the minimum fee for subsequent devices in mandatory audits. This episode details what these changes mean for manufacturers and how to prepare your regulatory strategy and budget.
Australia's Therapeutic Goods Administration (TGA) has clarified that many AI-powered digital scribes are considered medical devices, not simple administrative tools. Following a review published on October 16, 2023, the TGA found that 8 of 12 reviewed products were likely unapproved medical devices. This episode breaks down the TGA's reasoning, focusing on how a software's intended purpose—such as summarizing or analyzing clinical information—triggers regulatory oversight. We discuss the immediate compliance obligations for manufacturers and provide practical steps for developers of Software as a Medical Device (SaMD) to navigate this evolving regulatory landscape.
On October 14, 2026, Japan's PMDA published its draft guidance, 'Review Points for Medical Devices Utilizing Generative AI.' This episode explores the key safety and performance evaluation criteria that manufacturers must understand to successfully bring advanced AI-enabled medical devices to the Japanese market. We cover the PMDA's expectations for data quality, AI model lifecycle management, transparency, and risk management, providing practical steps for regulatory and quality teams to prepare for these new requirements.